Obesity drug trial pulled before it even started
NCT ID NCT06970405
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This study was designed to test an experimental drug called garetosmab in otherwise healthy men and postmenopausal women with obesity. The goal was to check the drug's safety and how it affects hormones and blood clotting. However, the study was withdrawn before any participants were enrolled, so no results are available.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- garetosmab (an experimental drug)
- What could go wrong
- The study was withdrawn before any participants were enrolled, so no data was collected. It is unknown if garetosmab would have been safe or effective for obesity.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OBESITY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new stomach and gut bypass surgery tackle obesity and diabetes?
- Can a Two-Drug combo tip the scales against obesity?
- Can Weight-Loss surgery change how medications work?
- Coffee grounds probiotic could reshape gut health and fight inflammation
- Can shedding pounds reboot the Heart's exercise engine?
- Can stomach surgery alter how painkillers work?